{"id":941984,"date":"2026-03-04T09:35:13","date_gmt":"2026-03-04T14:35:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/"},"modified":"2026-03-04T09:35:13","modified_gmt":"2026-03-04T14:35:13","slug":"aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/","title":{"rendered":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million"},"content":{"rendered":"
\n

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)<\/strong> \u2013 AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of its lead product, Ampligen\u00ae (rintatolimod), for the treatment of late-stage pancreatic cancer \u2013 a lethal and unmet global health problem \u2013 today announced the preliminary results of its previously announced rights offering (the \u201cRights Offering\u201d) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.<\/p>\n

Each right entitled the holder to purchase one unit (\u201cUnit\u201d), at a subscription price of $1,000 per Unit, consisting of one share of the Company\u2019s Series G Convertible Preferred Stock (the \u201cPreferred Stock\u201d), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company\u2019s Common Stock (the \u201cWarrants\u201d).<\/p>\n

The Company anticipates the closing of the Rights Offering will occur on or about March 6, 2026, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.<\/p>\n

Maxim Group LLC acted as dealer-manager for the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com<\/u><\/a> or telephone at (212) 895-3745.<\/p>\n

The Company\u2019s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (\u201cSEC\u201d) on February 10, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s website at http:\/\/www.sec.gov<\/a>.<\/p>\n

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n

\n About AIM ImmunoTech<\/strong>
\n \n <\/p>\n

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen\u00ae (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.<\/p>\n

\n Forward Looking Statements<\/strong>
\n \n <\/p>\n

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen\u00ae will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company\u2019s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen\u00ae will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen\u00ae will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company\u2019s reports filed with the SEC, on the Company\u2019s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.<\/p>\n

Please review the \u201cRisk Factors\u201d section in the Company\u2019s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at\u00a0www.aimimmuno.com<\/a>. The information found on the Company\u2019s website is not incorporated by reference herein and is included for reference purposes only.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
IR Contact:\r\n\r\nJTC Team, LLC\r\n\r\nJenene Thomas\r\n\r\n908.824.0775\r\n\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) \u2013 AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of its lead product, Ampligen\u00ae (rintatolimod), for the treatment of late-stage pancreatic cancer \u2013 a lethal and unmet global health problem \u2013 today announced the preliminary results of its previously announced rights offering (the \u201cRights Offering\u201d) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer … <\/p>\n
Continue reading “AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941984","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) \u2013 AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of its lead product, Ampligen\u00ae (rintatolimod), for the treatment of late-stage pancreatic cancer \u2013 a lethal and unmet global health problem \u2013 today announced the preliminary results of its previously announced rights offering (the \u201cRights Offering\u201d) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer … Continue reading "AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T14:35:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million\",\"datePublished\":\"2026-03-04T14:35:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/\"},\"wordCount\":949,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/\",\"name\":\"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=\",\"datePublished\":\"2026-03-04T14:35:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk","og_description":"OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) \u2013 AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of its lead product, Ampligen\u00ae (rintatolimod), for the treatment of late-stage pancreatic cancer \u2013 a lethal and unmet global health problem \u2013 today announced the preliminary results of its previously announced rights offering (the \u201cRights Offering\u201d) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer … Continue reading \"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-04T14:35:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million","datePublished":"2026-03-04T14:35:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/"},"wordCount":949,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/","name":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=","datePublished":"2026-03-04T14:35:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQ4OSM3NDY2NTkwIzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941984"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941984\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}